GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.

GSK Announces Extension of FDA Review for Rare Blood Therapy

Bellus Health Inc

BELLUS Health Inc (TSX:BLU) said its shareholders overwhelmingly have approved a US$2 billion takeover by GSK PLC (LSE:GSK, NYSE:GSK). The late-stage biopharmaceutical firm said in a statement that almost 100% of shareholders at a special meeting voted in favor of the US$14.75 per share offer.

Bellus Health shareholders say yes to US$2B GSK takeover

A regulatory delay for GSK PLC (LSE:GSK, NYSE:GSK) with the 'centrepiece' drug of its US$2bn Sierra Oncology (NASDAQ:SRRA) acquisition last year "isn't necessarily a red flag", according to an analyst. The FTSE 100 pharma group revealed the US Food & Drug Administration (FDA) has extended the review period for momelotinib by three months with a final decision now expected in September 2023.

GSK delay for new drug with US regulator 'not necessarily a red flag' - analyst

British drugmaker GSK Plc on Friday said the U.S. Food and Drug Administration has extended the review period for its experimental drug momelotinib, which is designed to treat anaemic patients with a type of bone marrow cancer called myelofibrosis.

GSK says FDA extends review period for experimental drug momelotinib

GSK plc (NYSE:GSK ) Goldman Sachs 44th Annual Global Healthcare Conference Call June 13, 2023 12:20 PM ET Company Participants Tony Wood - Chief Scientific Officer Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Welcome everybody to our third session this morning at the Goldman Sachs Healthcare Conference. My name is Chris Shibutani along with the team, especially the team that's based in London, Shaan Kapadia, Seth James.

GSK plc (GSK) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

Hundreds of GSK workers will this month escalate an ongoing strike over a pay dispute, UK labour union Unite said on Thursday.

GSK employees to escalate strike action in June -union

The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.

GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults

The European Commission has approved GSK's respiratory syncytial virus (RSV) vaccine for older adults, the drugmaker said on Wednesday, making it the first shot in the region against the common respiratory disease that can be fatal for seniors.

EU gives final approval for GSK's RSV vaccine

AT&T

Verizon

With a new trading month already in full swing it is time, once again, to highlight some of my potential stock purchases. With the market still having a tough time in 2023 we see no shortages of stocks that are becoming fairly valued to undervalued and boasting higher yields. This month, I continue to look at some of the same names in months past.

June 2023 Stock Considerations

GSK said on Tuesday that the U.S. Food and Drug Administration had granted file acceptance for its cancer drug, Jemperli, when combined with chemotherapy to treat adult patients with certain types of endometrial cancer.

GSK's cancer drug Jemperli gets file acceptance from US FDA

PHILADELPHIA--(BUSINESS WIRE)--GSK announces the COiMMUNITY Initiative to help achieve higher adult vaccination rates in the US.

GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US

India's GlaxoSmithKline Pharmaceuticals Ltd reported an 8.6% fall in its pre-tax profit for the fourth quarter on Wednesday, hurt by the government's curbs on pricing of some essential medicines.

India's GlaxoSmithKline Pharma's pre-tax profit falls on govt pricing caps

GSK's operating income margin in Q1 2023 was 29.35%, showing an increase in the previous quarter and the last year. Vaccine sales were $2,493 million in Q1 2023, up 11.9% year-over-year, mainly due to Fluarix and FluLaval, which regulators approved to prevent influenza.

What To Expect From GSK In 2023

Shore Capital has examined the prospects of GSK PLC (LSE:GSK, NYSE:GSK)'s newly approved respiratory syncytial virus (RSV) vaccine, Arexvy, and believes it could eventually be a blockbuster several times over. Although the broker is keeping its forecast of $1bn sales for Arexvy by 2027, it suggests the vaccine's market opportunity at the peak of it sales could be $9bn a year.

GSK: So, just how big is the RSV opportunity? Up to $9bn, says one broker

Adaptive Biotechnologies

Exact Sciences

Medicine is not always simple. A drug that cures one patient can easily kill another, based on anything from their weight to their genes to anything else.

3 Personalized Medicine Stocks to Buy for Long-Time Returns

GSK PLC (LSE:GSK, NYSE:GSK) said it welcomed a legal ruling in Canada that saw a proposed class action made on behalf of users of a heartburn drug thrown out. The Brentford, UK-based pharmaceuticals giant noted the court said there was little evidence that ranitidine, or zantac, leads to an increased risk of developing any type of cancer.

GSK welcomes Zantac legal ruling in Canada

The global RSV vaccine market isn't all that big, and healthcare giants are battling for market share. Potential vaccines from Pfizer and Moderna have demonstrated high efficacy in late-stage trials.

The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer

Cardinal Health

Chubb

Diageo

General Electric

Illinois Tool Works

Johnson Controls

Kimberly-Clark

Coca-Cola

Leggett & Platt

Mondelez

Altria

Philip Morris

Markets continue to look shaky, real estate is starting to crack, precious metals doing pretty well but are still manipulated well below true value and the crypto world has started to thaw but nowhere near mania mode, yet. These lows and uncertain times are when the real profits and income is generated for the future.

Dividend Portfolio Update: April 2023

Broadstone Net Lease

Bank of Nova Scotia

Chimera Investment

Canadian Imperial Bank of Commerce

Cisco Systems

Haleon PLC

Iron Mountain

Johnson & Johnson

MDU Resources Group

Medical Properties Trust

NetApp

Realty Income Corp

Orion Office REIT

Paramount Global

SoFi Technologies

South32 Ltd

Invesco S&P 500 High Dividend Low Volatility ETF

TotalEnergies SE

Woodside Energy Group Ltd

Investing in dividend stocks allows you to earn dividend income, the best passive income stream. Dividend Income is my primary vehicle on the road to Financial Freedom, which you can see through my Dividend Portfolio.

Dividend Income Summary: Lanny's April 2023 Summary

GSK's Arexvy respiratory syncytial virus vaccine has been approved by the U.S. Food and Drug Administration for people 60 years old and older.

FDA Approves GSK's RSV Vaccine for Older Adults

Decades after the first attempt was made, an RSV vaccine has finally been approved by the FDA.

FDA Approves First-Ever RSV Vaccine After Brutal 2022 Season

The Food and Drug Administration on Wednesday approved GSK's GSK vaccine for respiratory syncytial virus (RSV), a highly contagious virus that causes lung and breathing-passage infections.

FDA approves GSK RSV vaccine

PHILADELPHIA--(BUSINESS WIRE)-- #GSK--US FDA approves GSK's AREXVY, the world's first respiratory syncytial virus (RSV) vaccine for older adults.

US FDA Approves GSK's AREXVY, the World's First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

GSK stock jumped Wednesday after the drugmaker won the first-ever approval for an RSV vaccine, leading rivals Pfizer and Moderna. The post GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish Line appeared first on Investor's Business Daily.

GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish Line

The FDA's approval is a victory for GSK in a race against Pfizer and Moderna to bring a shot that targets respiratory syncytial virus to the market.

FDA approves GSK's RSV vaccine for older adults, world's first shot against virus

News for GlaxoSmithKline Stock (GSK)